Solventum Quarterly Income Statement
NYSE: SOLVHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Solventum revenue and earnings
In the quarter ended Jun 30, 2026, Solventum generated $2.21 billion in revenue, up 2.2% from the same quarter a year earlier. Net income was $92.0 million (+2.2% year over year), for a net margin of 4.2% versus a median of 4.2% in the prior 5 quarters. Gross margin was 58.2% (up from 54.4%) and operating margin 8.2%.
Diluted earnings per share came in at $0.53, up from $0.51.
Summary generated from market data by MetaCap's automated system. Methodology
Solventum income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.21B | 2.01B | 2.00B | 2.10B | 2.16B | 2.07B | 2.08B | 2.08B | 2.08B | 2.02B | 2.04B | 2.07B |
| Revenue growth (YoY) | +2.22% | -3.04% | -3.71% | +0.67% | +3.84% | +2.68% | +1.92% | +0.39% | +0.24% | +0.25% | — | — |
| Gross Profit | 1.29B | 1.10B | 1.03B | 1.14B | 1.18B | 1.11B | 1.12B | 1.17B | 1.14B | 1.17B | 1.16B | 1.21B |
| Operating Expenses | 1.10B | 1.02B | 903.00M | -555.00M | 961.00M | 962.00M | 983.00M | 890.00M | 893.00M | 791.00M | 752.00M | 705.00M |
| Research & Development | 178.00M | 189.00M | 175.00M | 183.00M | 189.00M | 193.00M | 199.00M | 189.00M | 192.00M | 195.00M | 190.00M | 180.00M |
| Selling, General & Admin | 927.00M | 827.00M | 759.00M | 780.00M | 772.00M | 769.00M | 784.00M | 701.00M | 701.00M | 596.00M | 618.00M | 525.00M |
| Operating Income | 181.00M | 81.00M | 124.00M | 1.69B | 214.00M | 152.00M | 136.00M | 275.00M | 244.00M | 381.00M | 406.00M | 504.00M |
| Other Income (Expense) | -9.00M | -4.00M | -15.00M | -5.00M | -8.00M | -11.00M | -16.00M | -1.00M | -34.00M | -13.00M | -15.00M | -4.00M |
| Pretax Income | 108.00M | 16.00M | 58.00M | 1.51B | 103.00M | 38.00M | 13.00M | 167.00M | 96.00M | 329.00M | 391.00M | 500.00M |
| Income Tax | 15.00M | 3.00M | -5.00M | 248.00M | 13.00M | -99.00M | -17.00M | 45.00M | 7.00M | 92.00M | 119.00M | 40.00M |
| Net Income | 92.00M | 13.00M | 63.00M | 1.27B | 90.00M | 137.00M | 31.00M | 122.00M | 89.00M | 237.00M | 272.00M | 460.00M |
| Net Income growth (YoY) | +2.22% | -90.51% | +103.23% | +937.70% | +1.12% | -42.19% | -88.60% | -73.48% | -72.27% | -19.11% | — | — |
| EPS (Basic) | 0.53 | 0.07 | 0.37 | 7.26 | 0.52 | 0.79 | 0.19 | 0.70 | 0.51 | 1.37 | 1.57 | 2.66 |
| EPS (Diluted) | 0.53 | 0.07 | 0.37 | 7.22 | 0.51 | 0.78 | 0.18 | 0.70 | 0.51 | 1.37 | 1.57 | 2.66 |
| Shares Outstanding (Basic) | 172.70M | 174.20M | — | 174.30M | 174.10M | 173.70M | — | 173.40M | 173.20M | 172.70M | — | 172.70M |
| Shares Outstanding (Diluted) | 173.30M | 175.50M | — | 175.40M | 175.20M | 174.80M | — | 173.90M | 173.50M | 172.70M | — | 172.70M |
| EBITDA | 314.00M | 216.00M | 241.00M | 1.81B | 336.00M | 281.00M | 286.00M | 408.00M | 377.00M | 520.00M | 545.00M | 648.00M |
| Gross Margin | 58.22% | 54.66% | 51.40% | 54.15% | 54.37% | 53.82% | 53.93% | 55.96% | 54.64% | 58.13% | 56.88% | 58.29% |
| Operating Margin | 8.19% | 4.04% | 6.21% | 80.63% | 9.90% | 7.34% | 6.55% | 13.21% | 11.73% | 18.90% | 19.94% | 24.30% |
| Net Margin | 4.16% | 65.00% | 3.15% | 60.40% | 4.16% | 6.62% | 149.00% | 5.86% | 4.28% | 11.76% | 13.36% | 22.18% |
This table shows 12 quarterly periods of Solventum's income statement, from Q2 2026 back to Q3 2023, across 18 line items including revenue, gross profit, operating expenses. Values in USD; B = billions, M = millions. Fiscal periods follow SOLV's reporting calendar. What is a income statement?